Inclusion Criteria:

          -  Patients with relapsed / refractory previously treated B cell malignancies (according
             to the World Health Organization classification; 2017)

          -  Chemotherapy-refractory disease

          -  Patients must have received adequate prior therapy including at least two lines of
             prior therapies including anthracycline-containing chemotherapy, anti-CD20 (cluster of
             differentiation antigen 20) therapies and/or Brutton's tyrosine kinase (BTK)
             inhibitors

          -  Patients treated with prior CD19 targeted molecules (e.g., Blincyto) must have
             confirmed CD19+ disease

          -  Patients must be ineligible for allogeneic stem cell transplant (SCT)

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1

          -  Estimated life expectancy of ≥ 12 weeks from the first day of SWI019 dose administered

          -  Willing to undergo pre- and post-treatment core needle biopsy

          -  Adequate hematological, renal, pulmonary, cardiac, and liver function

          -  Resolved adverse events of any prior therapy to either baseline or CTCAE Grade ≤1

          -  Women of childbearing potential, a negative pregnancy test and must agree to practice
             effective birth control

          -  Men sexually active with female partners of child bearing potential must agree to
             practice effective contraception

          -  Willing and able to comply with scheduled visits, treatment plan, laboratory tests and
             other procedures

        Exclusion Criteria:

          -  Patients diagnosed with disease histologies including pediatric lymphomas/leukemias,
             Burkitt lymphoma, lymphoplasmacytic lymphomas, monoclonal gammopathy of undetermined
             significance (MGUS), T-cell histiocyte large B cell lymphoma

          -  Pregnant or lactating women

          -  Active bacterial, viral, and fungal infections

          -  History of allogeneic stem cell transplantation

          -  Treatment with any prior CD19 or CD20 CAR-T

          -  Patients receiving live (attenuated) vaccines within 4 weeks of screening visit or
             need for live vaccine on study

          -  Patients with known active central nervous system (CNS) disease. Patients with prior
             CNS disease that has been effectively treated may be eligible

          -  History of Class III or IV New York Heart Association (NYHA) heart failure, myocardial
             infarction, unstable angina or other significant cardiac disease within 6 months of
             screening

          -  Involvement of cardiac tissue by lymphoma

          -  Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura (ITP)

          -  HIV-1 and HIV-2 antibody positive patients